MA53236A - Traitement des malignités des lymphocytes b - Google Patents

Traitement des malignités des lymphocytes b

Info

Publication number
MA53236A
MA53236A MA053236A MA53236A MA53236A MA 53236 A MA53236 A MA 53236A MA 053236 A MA053236 A MA 053236A MA 53236 A MA53236 A MA 53236A MA 53236 A MA53236 A MA 53236A
Authority
MA
Morocco
Prior art keywords
malignities
lymphocyte
treatment
lymphocyte malignities
Prior art date
Application number
MA053236A
Other languages
English (en)
Inventor
Daniel P Gold
Original Assignee
Mei Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mei Pharma Inc filed Critical Mei Pharma Inc
Publication of MA53236A publication Critical patent/MA53236A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
MA053236A 2018-08-14 2019-08-13 Traitement des malignités des lymphocytes b MA53236A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862718929P 2018-08-14 2018-08-14
US201862775797P 2018-12-05 2018-12-05
US201962836511P 2019-04-19 2019-04-19

Publications (1)

Publication Number Publication Date
MA53236A true MA53236A (fr) 2021-06-23

Family

ID=69525845

Family Applications (1)

Application Number Title Priority Date Filing Date
MA053236A MA53236A (fr) 2018-08-14 2019-08-13 Traitement des malignités des lymphocytes b

Country Status (14)

Country Link
US (1) US20210299134A1 (fr)
EP (1) EP3836935A4 (fr)
JP (1) JP2021534115A (fr)
KR (1) KR20210043635A (fr)
CN (1) CN112888441A (fr)
AU (1) AU2019321432A1 (fr)
BR (1) BR112021002760A2 (fr)
CA (1) CA3109184A1 (fr)
IL (1) IL280726A (fr)
MA (1) MA53236A (fr)
MX (1) MX2021001606A (fr)
SG (1) SG11202101450VA (fr)
TW (1) TW202021591A (fr)
WO (1) WO2020036999A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012135160A1 (fr) 2011-03-28 2012-10-04 Pathway Therapeutics Inc. (aralkylamino et hétéroarylalkylamino alpha-substitués)pyrimidinyl- et 1,3,5-triazinylbenzimidazoles, compositions pharmaceutiques contenant ceux-ci et ces composés pour utilisation dans le traitement de maladies prolifératives
KR20240097982A (ko) 2017-05-23 2024-06-27 메이 파마, 아이엔씨. 병용 요법
MA49921A (fr) 2017-08-14 2021-05-12 Mei Pharma Inc Polythérapie

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2648676A4 (fr) * 2010-12-06 2016-05-04 Follica Inc Procédés destinés à traiter la calvitie et à favoriser la croissance des cheveux
WO2012135160A1 (fr) * 2011-03-28 2012-10-04 Pathway Therapeutics Inc. (aralkylamino et hétéroarylalkylamino alpha-substitués)pyrimidinyl- et 1,3,5-triazinylbenzimidazoles, compositions pharmaceutiques contenant ceux-ci et ces composés pour utilisation dans le traitement de maladies prolifératives
WO2016049214A1 (fr) * 2014-09-23 2016-03-31 Genentech, Inc. Procédé d'utilisation d'immunoconjugués anti-cd79b
WO2017007658A1 (fr) * 2015-07-07 2017-01-12 Rigel Pharmaceuticals, Inc. Combinaison à médiation immunitaire pour le traitement du cancer
WO2017035234A1 (fr) * 2015-08-24 2017-03-02 Epizyme, Inc. Méthode de traitement du cancer
KR102565885B1 (ko) * 2016-07-20 2023-08-09 유니버시티 오브 유타 리서치 파운데이션 Cd229 car t 세포 및 이의 사용 방법
US20190201409A1 (en) * 2016-09-19 2019-07-04 Mei Pharma, Inc. Combination therapy
WO2018060833A1 (fr) * 2016-09-27 2018-04-05 Novartis Ag Schéma posologique pour l'alpelisib, un inhibiteur de la phosphatidylinositol 3-kinase spécifique de l'isoforme alpha
WO2018082444A1 (fr) * 2016-11-02 2018-05-11 叶宝欢 Composé de pyrazolopyrimidine en tant qu'inhibiteur de pi3k et son utilisation
MA49921A (fr) * 2017-08-14 2021-05-12 Mei Pharma Inc Polythérapie

Also Published As

Publication number Publication date
SG11202101450VA (en) 2021-03-30
AU2019321432A1 (en) 2021-03-25
JP2021534115A (ja) 2021-12-09
US20210299134A1 (en) 2021-09-30
EP3836935A1 (fr) 2021-06-23
MX2021001606A (es) 2021-04-19
EP3836935A4 (fr) 2022-09-14
BR112021002760A2 (pt) 2021-05-11
WO2020036999A1 (fr) 2020-02-20
TW202021591A (zh) 2020-06-16
CN112888441A (zh) 2021-06-01
KR20210043635A (ko) 2021-04-21
CA3109184A1 (fr) 2020-02-20
IL280726A (en) 2021-03-25

Similar Documents

Publication Publication Date Title
EP3813647A4 (fr) Stimulation multimodale de traitement des tremblements
EP3765960A4 (fr) Traitement de flux d'événements
EP3779023A4 (fr) Appareil de traitement de vêtements
MA47719A (fr) Esketamine pour le traitement de la dépression
EP3538548A4 (fr) Variants d'il-2 pour le traitement de maladies auto-immunes
MA45192A (fr) Traitement d'association
EP3448875A4 (fr) Compositions pour le traitement de maladies
EP3448987A4 (fr) Compositions pour le traitement de maladies
EP3832004A4 (fr) Appareil de traitement de vêtements
EP3503890A4 (fr) Utilisation de la pridopidine pour le traitement des dystonies
EP3362065A4 (fr) Polythérapie pour le traitement de malignités
MA47820A (fr) Traitement de la glycogénose de type iii
EP3749064A4 (fr) Machine de traitement au plasma
EP3866777A4 (fr) Polythérapie pour le traitement de maladies inflammatoires
EP3740246C0 (fr) Perturbation du complexe linc pour le traitement de laminopathies
EP3316887A4 (fr) Inhibiteurs de gls1 pour le traitement de maladies
EP3773221A4 (fr) Traitement pour l'hydrocéphalie
MA53741A (fr) Procédés de traitement de troubles myéloprolifératifs
EP3735209A4 (fr) Traitement de la progression de la myopie
EP3933099A4 (fr) Appareil de traitement de vêtements
EP3347032A4 (fr) Traitement de l'ascite
EP3908292A4 (fr) Thérapie améliorée à lymphocytes t ciblés pour le traitement du myélome multiple
EP3881566A4 (fr) Traitement audio
MA51525A (fr) Traitement de minéraux
EP3829619A4 (fr) Traitement de la mucopolysaccharidose iva